Copyright
©The Author(s) 2019.
World J Gastroenterol. Jul 14, 2019; 25(26): 3426-3437
Published online Jul 14, 2019. doi: 10.3748/wjg.v25.i26.3426
Published online Jul 14, 2019. doi: 10.3748/wjg.v25.i26.3426
Variable | Whole population | Readmitted | Non-readmitted | P-value |
(n = 213) | (n = 65) | (n = 148) | ||
Age (yr), mean (SD) | 57 (11) | 56 (11) | 57 (10) | 0.536 |
Gender (male) | 153 (72) | 44 (68) | 109 (74) | 0.374 |
Etiology, n (%) | 0.946 | |||
HBV | 116 (54) | 37 (57) | 79 (53) | |
HCV | 13 (6) | 4 (6) | 9 (6) | |
Alcohol | 34 (16) | 9 (14) | 25 (17) | |
Other | 50 (23) | 15 (23) | 35 (24) | |
Comorbidity, n (%) | 68 (32) | 15 (23) | 53 (36) | 0.066 |
Diabetes, n (%) | 52 (24) | 12 (18) | 40 (27) | 0.180 |
Chronic kidney disease, n (%) | 6 (3) | 1 (2) | 5 (3) | 0.455 |
Hypertension, n (%) | 24 (11) | 5 (8) | 19 (13) | 0.274 |
Charlson comorbidity score, mean (SD) | 3.6 (1.2) | 3.6 (1.3) | 3.6 (1.2) | 0.936 |
Albumin (g/L), mean (SD)1 | 30 (4) | 30 (3) | 30 (4) | 0.454 |
Total bilirubin (μmol/L), mean (SD)1 | 48 (58) | 57 (75) | 44 (48) | 0.214 |
WBC (×109/L), mean (SD)1 | 3.8 (2.0) | 3.9 (1.8) | 3.8 (2.1) | 0.895 |
Serum sodium (mmol/L), mean (SD)1 | 139.0 (4.6) | 138.0 (3.5) | 139.0 (5.0) | 0.576 |
Serum potassium (mmol/L), mean (SD)1 | 3.9 (0.5) | 3.9 (0.5) | 3.9 (0.5) | 0.786 |
SCr (μmol/L), mean (SD)1 | 85 (95) | 95 (157) | 80 (45) | 0.441 |
PTA (%), mean (SD)1 | 52 (17) | 47 (17) | 55 (16) | 0.001 |
INR, mean (SD)1 | 1.7 (0.5) | 1.9 (0.6) | 1.6 (0.5) | 0.001 |
Hb (g/L), mean (SD)1 | 92 (20) | 85 (15) | 95 (21) | 0.001 |
PLT (×109/L), mean (SD)1 | 87 (68) | 94 (71) | 84 (67) | 0.350 |
Ascites, n (%)1 | 21 (10) | 11 (17) | 10 (7) | 0.022 |
HRS during hospital stay, n (%)1 | 4 (2) | 2 (3) | 2 (1) | 0.393 |
AKI during hospital stay, n (%)1 | 1 (0.5) | 0 (0) | 1 (0.7) | 0.507 |
ACLF during hospital stay, n (%)1 | 9 (4) | 2 (3) | 7 (5) | 0.581 |
MELD score, mean (SD)1 | 12.9 (5.8) | 12.7 (5.2) | 13.0 (6.0) | 0.719 |
Length of hospital stay (d), mean (SD)1 | 16 (13) | 15 (13) | 16 (13) | 0.646 |
Artificial liver use, n (%)1 | 4 (2) | 2 (3) | 2 (1) | 0.393 |
Anti-HE treatment course (d), mean (SD)1 | 11 (8) | 12 (9) | 10 (7) | 0.159 |
Preventing HE with medications post discharge, n (%) | 130 (61) | 40 (62) | 90 (61) | 0.920 |
Progression to HCC, n (%) | 27 (13) | 8 (12) | 19 (13) | 0.915 |
- Citation: Hu XP, Gao J. International normalized ratio and Model for End-stage Liver Disease score predict short-term outcome in cirrhotic patients after the resolution of hepatic encephalopathy. World J Gastroenterol 2019; 25(26): 3426-3437
- URL: https://www.wjgnet.com/1007-9327/full/v25/i26/3426.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i26.3426